Sarepta Therapeutics, Inc. (SRPT) Stock

Sarepta Therapeutics, Inc. (SRPT) is a Healthcare stock trading at $17.55 (as of 2026-06-18), with a market capitalization of $1.89B and a trailing P/E of 51.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on therapies for rare genetic diseases, including RNA-targeted treatments and gene therapies. It markets EXONDYS 51 and VYONDYS 53 for Duchenne muscular dystrophy based on specific dystrophin gene exon-skipping mutations, and is developing additional programs for related targets.

Valuation — source: SEC EDGAR (first-party)
Price$17.55
Market Cap$1.89B
P/E Ratio51.1
EV / EBITDA538.3
Price / Book1.25
Price / Sales0.86
DCF Value (model)$-49.99
DCF Upside vs Price-384.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.20B
Net Margin-32.5%
Return on Equity4.3%
Debt / Equity0.56
Current Ratio4.63
Revenue Growth (YoY)15.6%
EPS Growth (YoY)-388.7%
FCF Growth (YoY)-10.3%
Financial Health — source: SEC EDGAR
Altman Z-Score-1.05 (distress)
Valuation vs Sector & Industry
Stock P/E51.1
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector143.6%
vs Industry195.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($321.07M)
Institutional Holders Tracked10
Congressional Trades (recent)7
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODouglas S. Ingram
Employees1,372
CountryUS
IPO Date1997-06-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Adaptive Biotechnologies Corporation (ADPT)
  • Immunome, Inc. (IMNM)
  • Ultragenyx Pharmaceutical Inc. (RARE)
  • Harmony Biosciences Holdings, Inc. (HRMY)
  • Recursion Pharmaceuticals, Inc. (RXRX)
  • Aurinia Pharmaceuticals Inc. (AUPH)
  • Maze Therapeutics, Inc. (MAZE)
  • Olema Pharmaceuticals, Inc. (OLMA)
SRPT earnings history · SRPT institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.